A Randomized Controlled Phase II Study of Nab-Paclitaxel vs. Paclitaxel plus Cisplatin in Concomitant Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Yang, W., Sr. [1 ]
机构：
[1] Guizhou Canc Hosp, Guiyang, Guizhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2171
引用
收藏
页码：E78 / E78
页数：1
相关论文
共 50 条
  • [41] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Yi Chen
    Jinyu Li
    Shixue Chen
    Yibao Zhang
    Yi Hu
    Guoqing Zhang
    Xiang Yan
    Shunchang Jiao
    Scientific Reports, 7
  • [42] Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Study
    Yu, N.
    Li, J.
    Chen, X.
    Wang, Z.
    Kang, X.
    Zhang, R.
    Qin, J.
    Zheng, Q.
    Feng, G.
    Deng, L.
    Zhang, T.
    Wang, W.
    Liu, W., Jr.
    Wang, J.
    Feng, Q.
    Lv, J.
    Chen, D.
    Zhou, Z.
    Xiao, Z.
    Li, Y.
    Bi, N.
    Li, Y.
    Wang, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E354 - E354
  • [43] Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
    Tabah, Ashley
    Huggar, David
    Kish, Jonathan
    Bapat, Bela
    Liassou, Djibril
    Gajra, Ajeet
    Miller, Talia
    Copher, Ronda
    Patel, Manali, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] nab-Paclitaxel plus Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology
    Gridelle, Cesare
    Chen, Tianlei
    Ko, Amy
    Ong, Teng Jin
    O'Brien, Mary
    Socinski, Mark
    Postmus, Pieter
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S213 - S213
  • [45] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada, Suguru
    Fujii, Tsutomu
    Takano, Nao
    Takami, Hideki
    Suenaga, Masaya
    Niwa, Yukiko
    Hayashi, Masamichi
    Iwata, Naoki
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer
    Iwai, Y.
    Koyama, N.
    Watanabe, Y.
    Miwa, C.
    Nagai, Y.
    Koyama, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [48] A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study
    Kogure, Y.
    Niwa, T.
    Yoshioka, H.
    Saka, H.
    Hata, A.
    Katakami, N.
    Ozawa, Y.
    Matsuo, N.
    Hoshino, T.
    Wakuda, K.
    Kenmotsu, H.
    Takahashi, T.
    Nosaki, K.
    Takenoyama, M.
    Tajima, M.
    Takahashi, K.
    Ando, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S355 - S356
  • [49] Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
    Ata, A.
    Kucuk, A.
    Eskici, S.
    Sanli, T.
    Nayir, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
    Liu, Ting
    Li, Qing
    Lin, Zhen
    Liu, Chunhua
    Pu, Wei
    Zeng, Shasha
    Lai, Jun
    Cai, Xuebin
    Zhang, Lisha
    Wang, Shuyang
    Chen, Miao
    Cao, Wei
    Gou, Hongfeng
    Zhu, Qing
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 602 - 615
12345